1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Prostatype Genomics AB (publ)

Prostatype Genomics AB (publ)

PROGEN.ST
Prostatype Genomics AB (publ)SE flagStockholm Stock Exchange
0.37
SEK
+0.04
- -
12.28MMarket Cap

Total Valuation

Prostatype Genomics AB (publ) carries a market capitalization of 12.28M, placing it among publicly traded companies globally. Its enterprise value stands at 138.56M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap12.28M
Enterprise Value138.56M

Share Statistics

Prostatype Genomics AB (publ) currently has 727,419.00 shares outstanding.

Shares Outstanding727,419.00
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 173.65, and the price-to-book ratio stands at -0.99.

PE RatioN/A
PS Ratio173.65
PB Ratio-0.99
P/TBV Ratio11.37
P/FCF Ratio-5.11
P/OCF Ratio-4.09

Enterprise Valuation

EV / Sales160.85
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Prostatype Genomics AB (publ) maintains a current ratio of 2.72, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.30, indicating elevated leverage, while an interest coverage ratio of -82.48 demonstrates limited ability to service its debt obligations.

Current Ratio2.72
Quick Ratio2.10
Debt / Equity2.30
Debt / EBITDA-0.02
Interest Coverage-82.48

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-107.59
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Stock Price Statistics

Prostatype Genomics AB (publ)'s stock has declined approximately -61.64948% over the past 52 weeks. The 50-day moving average sits at 0.56, while the 200-day moving average is 0.77.

Beta (5Y)N/A
52-Week Price Change-61.64948%
50-Day Moving Average0.56
200-Day Moving Average0.77
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Prostatype Genomics AB (publ) generated 861,445.00 in revenue and converted that into -34.04M in net income, yielding earnings per share of -68.19. EBITDA reached -33.63M, while operating income came in at -33.63M.

Revenue861,445.00
Gross Profit861,445.00
Operating Income-33.63M
Pretax Income-34.04M
Net Income-34.04M
EBITDA-33.63M
EBIT-33.63M
Earnings Per Share (EPS)-68.19

Balance Sheet

Prostatype Genomics AB (publ) holds 11.69M in cash and equivalents against 666,417.00 in total debt, resulting in a net debt position of -11.03M. Total book value stands at -151.05M, with working capital of 9.55M providing operational flexibility.

Cash & Cash Equivalents11.69M
Total Debt666,417.00
Net Debt-11.03M
Equity (Book Value)-151.05M
Book Value Per Share-377.64
Working Capital9.55M

Cash Flow

Prostatype Genomics AB (publ) produced -36.58M in operating cash flow over the past twelve months. After subtracting -69,910.00 in capital expenditures, free cash flow totaled -36.65M - equivalent to -91.64 per share.

Operating Cash Flow-36.58M
Capital Expenditures-69,910.00
Free Cash Flow-36.65M
FCF Per Share-91.64

Margins

Prostatype Genomics AB (publ) operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -3,903.98 and net profit margin of -3,951.20 provide insight into operational efficiency.

Gross Margin100.00
Operating Margin-3,903.98
Pretax Margin-3,951.20
Profit Margin-3,951.20
EBITDA Margin-3,903.98

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-26.43
FCF Yield-19.56

Stock Splits

Prostatype Genomics AB (publ)'s most recent stock split took place on October 31, 2024 with a 1000:1 split ratio.

Last Split Date10/31/2024
Split Ratio1000:1

Scores

Prostatype Genomics AB (publ) posts an Altman Z-Score of -1.46, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-1.46